1.Brasca, M.G.,Amboldi, N.,Ballinari, D., et al. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J. Med. Chem. 52(16), 5152-5163 (2009).
2.Caporali, S.,Alvino, E.,Starace, G., et al. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol. Res. 61(5), 437-448 (2010).
3.Degrassi, A.,Russo, M.,Nanni, C., et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-RasG12DLA2 lung adenocarcinoma transgenic mouse model: Evaluation by multimodality imaging. Mol. Cancer Ther. 9(3), 673-681 (2010).
|
